Inhaled Bevacizumab: A case study for delivery to the lung

Bevacizumab is a monoclonal antibody VEGF-inhibitor approved for treatment of cancers, including lung and colon. The goal of this study was to perform a real-time stability study of spray-dried bevacizumab dry powder formulation out to 24 months. 

Download the poster, presented at RDD Europe 2023, to learn more.

You may also be interested in:
Inhalation
Oral Drug Products
Spray-dried dispersions
Author(s):
Kimberly Shepard, Ph.D.
Associate Director, Principal Engineer, R&D
By clicking "Access Content" you agree to our Legal Disclaimer and the Lonza Privacy and Cookies Policy.

Latest content

Latest briefing from the Knowledge Center

Capsules in the palm of a hand
White paper
Unveiling Consumer Preferences for Oral Solid Dosage Forms. Capsules in the Spotlight
The article "Unveiling Consumer Preferences for Oral Solid Dosage Forms. Capsules in the Spotlight"...
3:2 cropped photo of pre-filled syringe
White paper
Straight to Market in an Autoinjector
A smart, data-driven approach to formulate biotherapeutics for PFS with confidence The global...
GS Effex® Cell Line - full image
Technical/Service brief
GS Effex® Cell Line for Enhanced Antibody Effector Function
GS Effex® derived from Lonza's leading GS Xceed® cell line, has been engineered to lack the enzyme...
Technical/Service brief
GS Xceed® Gene Expression System Brochure
GS Xceed® is a scalable, integrated, proven platform for developing biotherapeutics. The system is...
Lonza Bend Solid Form Services
White paper
Early Solid Form Screening: A Case Study
Solid form screening is highly customizable based on the phase of the drug development life cycle,...
lab workers on tablet
e-book
Accelerating Small Molecule Advancements
The increasing number of breakthroughs in small molecule drug development are exciting, but...
Article
Cis-targeted Immunotherapies Need Large CDMO Expertise but also Flexibility
Asher Biotherapeutics is developing a pipeline of cis-targeted immunotherapies that selectively...
Article
Transparent Communication Supports Tech Transfers of Cis-targeted Immunotherapies
Asher Biotherapeutics embarked on a search for a contract development and manufacturing organization...
Hot melt
Presentation (on-demand)
Rapid and Material-Sparing Feasibility Screening for Hot Melt Extrusion
Amorphous solid dispersions (ASD) offer a bioavailability enhancement drug delivery solution for...
Partner Visp_lab_RGB
Webinar (on-demand)
Meeting the Challenge of Rising API Complexity
The complexity of small molecule active pharmaceutical ingredients (APIs) is rising, bringing longer...
smm-webinar-1023-process-redesign
Webinar (on-demand)
Impact of Process Re-design on Sustainability in Pharmaceutical Small Molecule Manufacturing
A recent study revealed, that the pharmaceutical industry is significantly more emission-intensive...
Low Solubility Campaign Image
White paper
Increasing the Bioavailability of Oncology Drugs with Amorphous Solid Dosage Formulations
Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to...